Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.

Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A

The Journal of clinical endocrinology and metabolism1 Aug 2003Cited by 176 (Europe PMC)

PMID12915640DOI10.1210/jc.2002-021172PepBankPUB-12915640

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In short children born SGA, adult height did not differ significantly between GH doses (difference 0.3 SDS; 95% CI -0.2, 0.6; P > 0.2).
In plain wordsIn short children born SGA, adult height did not differ significantly between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeAdult height dose comparison
Study
n = 54
Comparator
3 IU/m(2).d
Outcome group
Linear growth · Musculoskeletal
Studied dose
6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean difference in adult height SDS between groups A and B
0.3 SDS
group A vs group B
95% CI of mean difference in adult height SDS
−0.2 to 0.6 SDS
group A vs group B
Source sentences
Summary
No significant differences between groups A and B were found for AH SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.2, 0.6; P > 0.2) and gain in height SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.1, 0.7; P > 0.1).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564006
02HumanRandomized controlled trialEfficacy outcome
In short children born SGA, height gain did not differ significantly between GH doses (difference 0.3 SDS; 95% CI -0.1, 0.7; P > 0.1).
In plain wordsIn short children born SGA, height gain did not differ significantly between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeHeight gain dose comparison
Study
n = 54
Comparator
3 IU/m(2).d
Outcome group
Linear growth · Musculoskeletal
Studied dose
6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean difference in gain in height SDS between groups A and B
0.3 SDS
group A vs group B
95% CI of mean difference in gain in height SDS
−0.1 to 0.7 SDS
group A vs group B
Source sentences
Summary
No significant differences between groups A and B were found for AH SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.2, 0.6; P > 0.2) and gain in height SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.1, 0.7; P > 0.1).
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564007
03HumanRandomized controlled trialEfficacy outcome
In short children born SGA, GH dose had no significant effect in regression analysis.
In plain wordsIn short children born SGA, growth hormone dose had no significant effect in the reported analysis.
Peptide
HGH (somatotropin)
Outcome
No significant changeAdjusted dose effect
Study
n: not reported in source
Comparator
other GH dose
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · 7.8 (1.7) yrAs given in this study (human).
Source sentences
Summary
GH dose had no significant effect.
3 context sentences(design, population, supporting numbers)
Summary · context
Multiple regression analysis indicated the following predictive variables for AH SDS: target height SDS, height SDS, and chronological age minus bone age (years) at the start of the study.
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564012
04HumanNon-randomized trialEfficacy outcome
In short children born SGA, 85% reached adult height above -2 SDS after long-term GH treatment.
In plain wordsIn short children born SGA, 85% reached adult height above -2 SDS after growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
Not applicableNormal adult height
Study
n = 54
Outcome group
Linear growth · Musculoskeletal
Studied dose
3 or 6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
children with adult height above -2 SDS
85%
GH-treated children
Source sentences
Summary
GH treatment resulted in an AH above -2 SDS in 85% of the children after a mean (+/-SD) GH treatment period of 7.8 (1.7) yr.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564001
05HumanNon-randomized trialEfficacy outcome
In short children born SGA, mean adult height was -1.1 (0.7) SDS with low-dose GH.
In plain wordsIn short children born SGA, mean adult height was -1.1 SDS with low-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
Not applicableAdult height low dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
3 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean adult height
−1.1 SDS
group A, 3 IU/m(2).d
SD of mean adult height
0.7 SDS
group A, 3 IU/m(2).d
Source sentences
Summary
The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (+/-SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564002
06HumanNon-randomized trialEfficacy outcome
In short children born SGA, mean adult height was -0.9 (0.8) SDS with high-dose GH.
In plain wordsIn short children born SGA, mean adult height was -0.9 SDS with high-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
Not applicableAdult height high dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean adult height
−0.9 SDS
group B, 6 IU/m(2).d
SD of mean adult height
0.8 SDS
group B, 6 IU/m(2).d
Source sentences
Summary
The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (+/-SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564003
07HumanNon-randomized trialEfficacy outcome
In short children born SGA, height gain was 1.8 (0.7) SDS with low-dose GH.
In plain wordsIn short children born SGA, height increased by 1.8 SDS with low-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight gain low dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
3 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean gain in height
1.8 SDS
group A, 3 IU/m(2).d
SD of mean gain in height
0.7 SDS
group A, 3 IU/m(2).d
Source sentences
Summary
The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (+/-SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564004
08HumanNon-randomized trialEfficacy outcome
In short children born SGA, height gain was 2.1 (0.8) SDS with high-dose GH.
In plain wordsIn short children born SGA, height increased by 2.1 SDS with high-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight gain high dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean gain in height
2.1 SDS
group B, 6 IU/m(2).d
SD of mean gain in height
0.8 SDS
group B, 6 IU/m(2).d
Source sentences
Summary
The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (+/-SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564005
09HumanNon-randomized trialEfficacy outcome
In short children born SGA, target-height-corrected adult height was -0.2 (0.8) SDS with low-dose GH.
In plain wordsIn short children born SGA, adult height corrected for target height was -0.2 SDS with low-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
Not applicableTarget-corrected adult height low dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
3 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean target-height-corrected adult height
−0.2 SDS
group A, 3 IU/m(2).d
SD of mean target-height-corrected adult height
0.8 SDS
group A, 3 IU/m(2).d
Source sentences
Summary
When corrected for target height, the mean corrected AH SDS was -0.2 (0.8) for group A and -0.4 (0.9) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564008
10HumanNon-randomized trialEfficacy outcome
In short children born SGA, target-height-corrected adult height was -0.4 (0.9) SDS with high-dose GH.
In plain wordsIn short children born SGA, adult height corrected for target height was -0.4 SDS with high-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
Not applicableTarget-corrected adult height high dose
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean target-height-corrected adult height
−0.4 SDS
group B, 6 IU/m(2).d
SD of mean target-height-corrected adult height
0.9 SDS
group B, 6 IU/m(2).d
Source sentences
Summary
When corrected for target height, the mean corrected AH SDS was -0.2 (0.8) for group A and -0.4 (0.9) for group B.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564009
11HumanNon-randomized trialEfficacy outcome
In short children born SGA, adult height was higher with GH than in untreated controls, whose mean was -2.3 (0.7) SDS (P < 0.001).
In plain wordsIn short children born SGA, adult height was higher with growth hormone than in untreated controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseAdult height versus untreated controls
Study
n: not reported in source
Comparator
non-GH-treated controls
Outcome group
Linear growth · Musculoskeletal
Studied dose
3 or 6 IU/m(2).d · 7.8 (1.7) yrAs given in this study (human).
Measurements
mean adult height of untreated control group
−2.3 SDS
non-GH-treated controls
SD of mean adult height of untreated control group
0.7 SDS
non-GH-treated controls
Source sentences
Summary
The mean (+/-SD) AH SDS of the control group [-2.3 (0.7)] was significantly lower than that of the GH-treated group (P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Fifteen non-GH-treated, non-GH-deficient, short children born SGA, with similar inclusion criteria, served as controls [mean (+/-SD) birth length, -3.3 (1.2); age at start, 7.8 (1.7) yr; height SDS at start, -2.6 (0.5)].
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564010
12HumanObservational studyOther
In GH-treated children born SGA, target height, baseline height, and chronological age minus bone age predicted adult height SDS.
In plain wordsIn children born SGA given growth hormone, baseline height, target height, and age relative to bone age predicted adult height.
Peptide
HGH (somatotropin)
Outcome
Not applicableAdult height predictors
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · 7.8 (1.7) yrAs given in this study (human).
Source sentences
Summary
Multiple regression analysis indicated the following predictive variables for AH SDS: target height SDS, height SDS, and chronological age minus bone age (years) at the start of the study.
2 context sentences(design, population, supporting numbers)
Summary · context
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial.
Summary · context
Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively).
Report a problemFND-1291564011

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01697644

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

Novo Nordisk A/Sn = 75Oct 1990 to May 2005

Foetal Growth Problem · Small for Gestational Age

Trial page ClinicalTrials.govUpdated 18 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.